tradingkey.logo
๎™

Bausch + Lomb Corp

BLCO
16.950USD
+0.050+0.30%
์ข…๊ฐ€ย 12/19, 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
6.00B์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™

์ž์„ธํ•œ ๋‚ด์šฉ์€ Bausch + Lomb Corp ํšŒ์‚ฌ

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

Bausch + Lomb Corp ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ BLCO
ํšŒ์‚ฌ ์ด๋ฆ„Bausch + Lomb Corp
์ƒ์žฅ์ผMay 06, 2022
CEOSaunders (Brenton L)
์ง์› ์ˆ˜13500
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒMay 06
์ฃผ์†Œ520 Applewood Crescent
๋„์‹œVAUGHAN
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX NASDAQ Basic NYSE
๊ตญ๊ฐ€Canada
์šฐํŽธ ๋ฒˆํ˜ธL4K 4B4
์ „ํ™”19082552864
์›น์‚ฌ์ดํŠธhttps://ir.bausch.com/
์ข…๋ชฉ ์ฝ”๋“œ BLCO
์ƒ์žฅ์ผMay 06, 2022
CEOSaunders (Brenton L)

Bausch + Lomb Corp์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Brenton L. (Brent) Saunders, J.D.
Mr. Brenton L. (Brent) Saunders, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
352.13K
+162.32%
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
77.36K
+8.63%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
68.18K
+35.10%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
66.56K
+2.53%
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
62.09K
+55.01%
Mr. A. Robert D. Bailey, J.D.
Mr. A. Robert D. Bailey, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
--
--
Ms. Sarah B. Kavanagh
Ms. Sarah B. Kavanagh
Independent Director
Independent Director
--
--
Mrs. Nathalie Bernier
Mrs. Nathalie Bernier
Independent Director
Independent Director
--
--
Mr. Andrew J. Stewart
Mr. Andrew J. Stewart
President - Global Pharmaceuticals and International Consumer
President - Global Pharmaceuticals and International Consumer
--
--
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Brenton L. (Brent) Saunders, J.D.
Mr. Brenton L. (Brent) Saunders, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
352.13K
+162.32%
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
77.36K
+8.63%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
68.18K
+35.10%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
66.56K
+2.53%
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
62.09K
+55.01%
Mr. A. Robert D. Bailey, J.D.
Mr. A. Robert D. Bailey, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
--
--

์ˆ˜์ต ๋ถ„์„

ํ†ตํ™”: USD๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Oct 6
ํ†ตํ™”: USD๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
์‚ฌ์—…๋ณ„USD
์ด๋ฆ„
์ˆ˜์ต
๋น„์œจ
OTC
482.00M
37.72%
Devices
472.00M
36.93%
Pharmaceuticals
260.00M
20.34%
Branded and other Generics
58.00M
4.54%
Other revenues
6.00M
0.47%
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
์‚ฌ์—…๋ณ„USD
์ด๋ฆ„
์ˆ˜์ต
๋น„์œจ
OTC
482.00M
37.72%
Devices
472.00M
36.93%
Pharmaceuticals
260.00M
20.34%
Branded and other Generics
58.00M
4.54%
Other revenues
6.00M
0.47%

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Nov 22
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Nov 22
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Bausch Health Companies Inc
87.65%
Icahn Enterprises LP
0.99%
Deutsche Bank Securities Inc.
0.99%
Alberta Investment Management Corporation
0.92%
Oaktree Capital Management, L.P.
0.92%
๊ธฐํƒ€
8.54%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Bausch Health Companies Inc
87.65%
Icahn Enterprises LP
0.99%
Deutsche Bank Securities Inc.
0.99%
Alberta Investment Management Corporation
0.92%
Oaktree Capital Management, L.P.
0.92%
๊ธฐํƒ€
8.54%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Corporation
87.66%
Hedge Fund
3.73%
Investment Advisor/Hedge Fund
3.07%
Research Firm
1.67%
Investment Advisor
1.65%
Holding Company
0.99%
Sovereign Wealth Fund
0.92%
Individual Investor
0.48%
Family Office
0.24%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Dec 8
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Dec 8
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2025Q4
247
42.63M
17.16%
+11.66K
2025Q3
260
42.62M
19.43%
+3.57M
2025Q2
253
39.09M
18.05%
+715.03K
2025Q1
249
38.33M
16.53%
-19.93M
2024Q4
239
35.61M
16.96%
-2.09M
2024Q3
234
37.72M
16.36%
-3.49M
2024Q2
237
40.61M
17.42%
+3.09M
2024Q1
226
37.49M
18.08%
-25.96M
2023Q4
216
38.90M
17.69%
-4.13M
2023Q3
198
43.02M
17.49%
-1.91M
๋” ๋ณด๊ธฐ

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
Bausch Health Companies Inc
310.45M
87.68%
--
--
Mar 24, 2025
Deutsche Bank Securities Inc.
3.41M
0.96%
-89.90K
-2.57%
Jun 30, 2025
Alberta Investment Management Corporation
3.27M
0.92%
+258.00K
+8.58%
Mar 31, 2025
Oaktree Capital Management, L.P.
2.52M
0.71%
+2.52M
--
Jun 30, 2025
GoldenTree Asset Management, LP
2.58M
0.73%
+334.92K
+14.90%
Jun 30, 2025
D. E. Shaw & Co., L.P.
2.61M
0.74%
+728.68K
+38.79%
Jun 30, 2025
Fidelity Management & Research Company LLC
771.84K
0.22%
+771.84K
--
Jun 30, 2025
Glenview Capital Management, LLC
1.55M
0.44%
+1.05M
+210.77%
Jun 30, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
์ด๋ฆ„
๋น„์œจ
Ballast Small/Mid Cap ETF
1.4%
Invesco RAFI Developed Mkts ex-US SM ETF
0.03%
BNY Mellon US Small Cap Core Equity ETF
0.03%
Schwab Fundamental International Small Equity ETF
0%
Goldman Sachs MarketBeta US 1000 Equity ETF
0%
Invesco Zacks Mid-Cap ETF
0%
QRAFT AI-Enhanced US Large Cap ETF
0%
AltShares Event-Driven ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
BNY Mellon US Mid Cap Core Equity ETF
0%
๋” ๋ณด๊ธฐ
Ballast Small/Mid Cap ETF
๋น„์œจ1.4%
Invesco RAFI Developed Mkts ex-US SM ETF
๋น„์œจ0.03%
BNY Mellon US Small Cap Core Equity ETF
๋น„์œจ0.03%
Schwab Fundamental International Small Equity ETF
๋น„์œจ0%
Goldman Sachs MarketBeta US 1000 Equity ETF
๋น„์œจ0%
Invesco Zacks Mid-Cap ETF
๋น„์œจ0%
QRAFT AI-Enhanced US Large Cap ETF
๋น„์œจ0%
AltShares Event-Driven ETF
๋น„์œจ0%
DFA Dimensional International Core Equity 2 ETF
๋น„์œจ0%
BNY Mellon US Mid Cap Core Equity ETF
๋น„์œจ0%

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Bausch + Lomb Corp์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Bausch + Lomb Corp์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค:
Bausch Health Companies Inc๋Š” 310.45M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 87.68%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Deutsche Bank Securities Inc.๋Š” 3.41M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.96%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Alberta Investment Management Corporation๋Š” 3.27M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.92%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Oaktree Capital Management, L.P.๋Š” 2.52M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.71%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
GoldenTree Asset Management, LP๋Š” 2.58M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.73%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.

Bausch + Lomb Corp์˜ ์ƒ์œ„ 3๋Œ€ ์ฃผ์ฃผ ์œ ํ˜•์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
Bausch + Lomb Corp์˜ ์ฃผ์š” ์ฃผ์ฃผ ์œ ํ˜• ์ƒ์œ„ 3๊ฐ€์ง€๋Š”
Bausch Health Companies Inc
Icahn Enterprises LP
Deutsche Bank Securities Inc.์ž…๋‹ˆ๋‹ค.

Bausch + Lomb Corp(BLCO)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2025Q4 ๊ธฐ์ค€์œผ๋กœ, Bausch + Lomb Corp์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 247๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 42.63M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 17.16%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q3 ๋Œ€๋น„ -2.27% ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.

Bausch + Lomb Corp์˜ ์ตœ๋Œ€ ์ˆ˜์ต์›์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
FY2025Q2 ๊ธฐ์ค€, Bausch + Lomb Corp์˜ OTC ๋ถ€๋ฌธ์ด ๊ฐ€์žฅ ๋†’์€ ๋งค์ถœ์„ ๊ธฐ๋กํ–ˆ์œผ๋ฉฐ, ๊ธˆ์•ก์€ 482.00M๋กœ ์ „์ฒด ๋งค์ถœ์˜ 37.72%๋ฅผ ์ฐจ์ง€ํ–ˆ์Šต๋‹ˆ๋‹ค.
KeyAI
๎™